Provider review
MEDGm Review: A 100% Success Probability, Before Any Clinician Looks
When we went through MEDGm's intake in September 2026, a screen before payment told us our "Success probability" was 100% and our plan was "approved" — while the site's own footer says a clinician decides whether you qualify after you pay. No trial of any drug has reported certainty. The same page heads its testimonials "Clinical results you can trust", and its footer says every one of those results is self-reported by customers, not drawn from a trial.
Partner link — we may earn a commission. How we’re paid
Visit MEDGmOf MEDGm’s 2 dated product claims documented below, 1 is consistent with the cited evidence. Comparable upfront pricing is not established here. A matching claim does not mean the compounded product was tested or FDA-approved.
Its intake called us a clinical match with a 100% success probability before any clinician had looked, and it labels self-reported customer results as clinical.
Worth trusting if
- You want the dispensing pharmacies named, which they are, with addresses and telephone numbers
- You want a plain statement that compounded medicines are not FDA-approved, which the site gives
Be skeptical if
- You read the "Clinical results you can trust" testimonials as trial evidence, because the site's own footer says they are self-reported customer data
- You take a pre-payment screen calling you a clinical match as a medical opinion, because no clinician has seen you at that point
- You are budgeting from the advertised figure, which is a first-month coupon rate rather than the standing one
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Compounded
Phase 3 trials
Named
None found
Provenance
Products reviewed at MEDGm
These evidence cards classify the treatments evaluated in this review. Confirm the exact medicine and formulation proposed for your prescription with the care team.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded semaglutide injection — Advertised as starting at $169 a month, which the site says covers the consultation and the first month of medication; the standing month-to-month rate after that is $299.
- Compounded tirzepatide injection — Advertised from $279 as a first-month rate; the standing month-to-month rate is $399.
Evidence
Has the molecule been tested for what it is sold for?
Each row summarizes human evidence for the molecule and the use being advertised. Results apply to the product, dose, population and outcome studied; they do not establish that this provider’s preparation or program produces the same results. Compounded drugs are not FDA-approved. Evidence for one use should not be assumed to support another.
2
Products with human evidence
For the advertised use, out of 2 products reviewed here. The evidence concerns the molecule, not MEDGm's service.
2
Registry records cited
Distinct ClinicalTrials.gov records cited across the reviewed products. Registration alone does not establish that a treatment works.
The comparison
What they claim, against what the trials show
Each claim below is quoted word for word from MEDGm’s own page. Tap a row to see the quote, the trials behind it, and why it got that verdict.
Compounded semaglutide injectionSemaglutide · Compounded (503A)Claim matches the trials
“Will this work for me? Complete our short quiz and a licensed provider reviews your health history and goals to determine your eligibility. Our providers offer personalized GLP-1 compounded treatments tailored to your specific health journey to help you reach your goals under professional medical care.”
Read on the MEDGm site, September 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. 68 weeks in adults with a body-mass index of 30 or above, or 27 or above with at least one weight-related condition.
This answer makes no promise and leaves eligibility to a licensed provider, which is the right shape for it. Semaglutide's weight-loss evidence is phase 3: STEP 1 enrolled 1,961 adults at a body-mass index of 30 or above, or 27 or above with a weight-related condition, and that is the population the drug was shown to work in. One thing the answer leaves out: the site's own footer says that provider meets you after payment, not after the quiz.1
Compounded tirzepatide injectionTirzepatide · Compounded (503A)No trial supports this claim
“STATUS: CLINICAL MATCH. Success probability 100%. Expected response: Strong. [Name]'s GLP-1 prescription plan approved!”
Read on the MEDGm site, September 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. 72 weeks, adults with obesity or overweight and no diabetes. Reported a mean weight reduction, a distribution of responses, and a proportion of participants who did not reach any given threshold. No trial of any drug has reported a success probability of 100%.
Three of these four lines are clinical assertions, and no clinician had made them. When we went through the intake in September 2026 with invented answers, this screen appeared before payment — while the site's own footer says an OpenLoop clinical professional meets the patient AFTER payment to determine whether they qualify. "Success probability 100%" is the part with no defensible reading: SURMOUNT-1 reported a mean, a spread and a share of participants who did not reach a given threshold, and no trial of any drug in any condition has ever reported certainty. "CLINICAL MATCH", "Expected response: Strong" and a plan "approved" are the vocabulary of a clinical decision, produced by a quiz.2
Dispensing chain
Who actually fills your prescription
- RedRock Pharmacy
- Health Warehouse
Read the full account
MEDGm names its dispensing pharmacies, including RedRock Pharmacy in St. George, Utah and Health Warehouse in Florence, Kentucky, with addresses and telephone numbers — real disclosure that most of this market does not offer. The same pharmacies are named by several other sellers we have reviewed; that is a shared vendor set and says nothing about who owns whom, and we draw no such conclusion. The prescribing side is not named at the individual level: the medical practice appears as OpenLoop, and no clinician, medical director or advisory name is published. The site's disclosure of what compounding means is better than most, and worth quoting in full because a shorter excerpt would misrepresent it: "Compounded GLP-1s are produced in FDA-regulated facilities. Although these facilities are highly regulated, the medications are not FDA-approved and have not been evaluated for safety, efficacy, or quality." That draws the right line between a facility being inspected and a product being approved.
Read on the MEDGm site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Not established in this source review
Certificate of analysis readable
A readable lot report was not verified here
Read the full testing account
No certificate of analysis, potency, purity or sterility result is published. What the site does publish, prominently, is a testimonial wall headed "Clinical results you can trust", with each quote labeled "Verified customer" beside a weight-loss figure. The same page's footer says those results are self-reported by customers, that none is associated with clinical trials, and that site materials "may be generated or enhanced using artificial intelligence technologies" with "no representation or warranty" as to their accuracy. It also says images may use models.
Read on the MEDGm site, September 2026.
Licensing
Licensed to dispense, and where
Coverage
MEDGm advertises the service as "100% Online — from consult to delivery", and notes separately that telemedicine regulations vary by state and that some states require a live video or telephone consultation before prescribing. No per-state list is published, so a reader cannot tell in advance which applies to them.
Read the full licensing claim
No clinician is named — no prescriber, no medical director, no advisory panel. The medical practice is identified as OpenLoop. The entity is MEDGm, LLC. The site states that a clinical professional meets the patient after payment to determine whether they qualify for a prescription.
Read on the MEDGm site, September 2026.
Regulatory
The FDA warning letter
No FDA warning letter found
Assessment
What holds up, and what does not
- It names its dispensing pharmacies with addresses and telephone numbers.
- Its compounding disclosure is accurate and unusually complete — it distinguishes a regulated facility from an approved product in the same sentence.
- It states plainly that compounded medications have not been evaluated for safety, efficacy or quality.
Show 2 more
- It notes that telemedicine rules vary by state and that some states require a live consultation before prescribing.
- No FDA warning letter against MEDGm, LLC or the named pharmacies.
- When we went through the intake, a pre-payment screen declared "STATUS: CLINICAL MATCH" and "Success probability 100%" before any clinician had seen anything.
- No trial of any drug has reported a success probability of 100%, and the trials for these molecules report a distribution of responses including non-responders.
- The site's own footer says a clinical professional determines whether a patient qualifies after payment, which the pre-payment screen pre-empts.
Show 5 more
- Testimonials sit under the heading "Clinical results you can trust" and carry a "Verified customer" label, while the footer says every result is self-reported and none comes from a clinical trial.
- The same footer says site materials may be generated or enhanced using artificial intelligence and declines to warrant their accuracy.
- The advertised entry prices are first-month coupon rates, not the standing ones.
- No clinician is named anywhere.
- Its peptide-adjacent lines — sleep, sexual health and hair loss — are all marked coming soon and cannot be bought.
Verdict
The bottom line
Two things here are better than the market average: the pharmacies are named, and the compounding disclosure is genuinely accurate. Everything clinical is worse. The intake hands you a "clinical match" with a "100% success probability" before a clinician has read a word, and the results offered as clinical are customers' own reports of their weight. Treat both as advertising, because that is what they are, and get an actual clinical opinion before you pay.
Opens MEDGm's website. A link is not a recommendation to take anything.
"Success probability 100%"
When we went through MEDGm's intake with invented answers in September 2026, a screen appeared before payment reading:
STATUS: CLINICAL MATCH
Success probability 100%
Expected response: Strong
"[Name]'s GLP-1 prescription plan approved!"
The site's own footer says an OpenLoop clinical professional meets the patient after payment to determine whether they qualify for a prescription. So at the moment those four lines appear, nobody clinical has looked at anything.
"Success probability 100%" is the line with no defensible reading. SURMOUNT-1 reported a mean reduction, a spread around it, and a share of participants who did not reach any given threshold. No trial of any drug, in any condition, has reported certainty.
The FAQ on the same page now handles eligibility well. Asked "Will this work for me?", it answers:
"Complete our short quiz and a licensed provider reviews your health history and goals to determine your eligibility."
That is the right answer. It is also the reason the intake screen is a problem: the page says a provider decides, and the intake announces the decision first.
Full analysis — 2 more sections"Clinical results you can trust" · What MEDGm gets right
"Clinical results you can trust"
MEDGm's GLP-1 page heads its testimonial wall "Clinical results you can trust", calls them "clinically-backed", and labels each quote "Verified customer", beside figures like "38 lbs on GLP-1s in 25 weeks".
The footer on the same page says what those results are:
"All claims and benefits on this website refer to self-reported data from GLP-1 clients… Clients reported their weight on their initial medical questionnaire and subsequently every 3-4 weeks."
And a paragraph later:
"No data, photos, claims, or any other information is associated with results derived from clinical trials, studies, or public information."
So the word "clinical" in the heading describes customers weighing themselves. The trial evidence for these drugs is real and strong — STEP 1 1 and SURMOUNT-1 2 — but it is not what this section shows you, and the site says so in its own small print. The same footer adds that site materials "may be generated or enhanced using artificial intelligence technologies" with "no representation or warranty… regarding the accuracy, completeness, or reliability of such content."
What MEDGm gets right
It names its dispensing pharmacies — RedRock Pharmacy and Health Warehouse among them — with addresses and telephone numbers. Most sellers in this market name none.
And its compounding disclosure is genuinely accurate. It is worth quoting whole, because a shorter excerpt would misrepresent it:
"Compounded GLP-1s are produced in FDA-regulated facilities. Although these facilities are highly regulated, the medications are not FDA-approved and have not been evaluated for safety, efficacy, or quality."
That is the correct distinction between a facility being inspected and a product being approved, and a lot of this market never draws it.
Questions
Frequently asked questions
Does the site really say my success probability is 100%?
That is what MEDGm's intake showed us in September 2026, on a screen before payment — alongside "STATUS: CLINICAL MATCH", "Expected response: Strong" and a plan marked approved. The site's own footer says a clinical professional determines whether you qualify after payment, so nobody clinical has seen anything at that point. No trial of any drug has ever reported a 100% success probability.
Are the testimonials real?
The site says they come from MEDGm patients, and that the images may use models. What it also says is that the results are self-reported: customers entered their own weight every three to four weeks, and the footer states that none of it is associated with clinical trials. That is worth knowing before reading a wall headed "Clinical results you can trust" as clinical evidence. The footer adds that site materials may be generated or enhanced using artificial intelligence and makes no representation as to their accuracy.
What will I actually pay?
More than the advertised figure after the first month. The entry prices shown before intake are first-month rates produced by an automatically applied coupon; the standing month-to-month rates are substantially higher for both molecules.
Which pharmacy fills the prescription?
MEDGm names several, including RedRock Pharmacy and Health Warehouse, with addresses and telephone numbers — genuine disclosure that most sellers here do not offer. It does not say which one fills which order. The same pharmacies are named by several other companies in this market; that is a shared vendor set and tells you nothing about ownership.
Can I buy a peptide here?
No. The sleep, sexual health and hair loss lines are all marked coming soon and none can be purchased. Only the GLP-1 products are actually for sale.
Glossary
Key terms
Show definitions
- Self-reported data
- Figures a customer supplies about themselves, such as their own weight on a questionnaire. Useful, but not a trial result: there is no control group, no blinding and no record of the people who stopped reporting.
Compare
Others selling what MEDGm sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Ranked
The lists MEDGm is on
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off MEDGm's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 2 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — 1,961 adults, entry at BMI ≥30 or ≥27 with at least one weight-related comorbidity. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT03548935
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — 2,539 adults, same entry floor; reported a mean reduction, a distribution of responses and a proportion not reaching each threshold. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT04184622
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.